Clinical trial KEYNOTE-585
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Merck |
| EudraCT Identifier | 2016-004408-76 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03221426 |
| Inclusion criteria | ECOG 0 or 1. Life expectancy superior to 6 months.Previously untreated localized gastric or GEJ adenocarcinoma. Adequate organ function. Plan to proceed to surgery following pre-operative chemotherapy. Be willing to provide tissue from a tumor lesion at |
| Last update |